Effect of celecoxib on symptoms of patients with Schizophrenia under Electroconvulsive Therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130723014122N2

Enrollment

Registered

2023-04-24

Start date

2023-04-21

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia.

Interventions

Intervention group: celecoxib + ECT and routine drugs, control group: placebo + ECT and routine drugs.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: patients with Schizophrenia under Electroconvulsive Therapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood biochemical indicators: CBC diffWBCBaselin monocyte LymphocyteESRCRP. Timepoint: Before the start of shock therapy, the end of the third session and the end of the sessions. Method of measurement: Review of clinical findings.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzad Maroufi

Sanandaj University of Medical Sciences

marufi@muk.ac.ir+98 87 1666 4646

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026